Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CORSNASDAQ:GWIINASDAQ:IQMDNASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORSCorsair Partnering$10.37$10.35$9.68▼$10.60$308.33M0.02128,468 shs13 shsGWIIGood Works II Acquisition$10.11$10.16$9.81▼$12.00$89.68M-0.022,195 shsN/AIQMDIntelligent Medicine Acquisition$11.04$10.72$9.97▼$11.22$64.75M0.0348,072 shsN/ASNTISenti Biosciences$2.21+4.7%$3.11$1.52▼$16.94$57.64M2.24809,682 shs53,101 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORSCorsair Partnering0.00%0.00%0.00%0.00%0.00%GWIIGood Works II Acquisition0.00%0.00%0.00%0.00%0.00%IQMDIntelligent Medicine Acquisition0.00%0.00%0.00%0.00%0.00%SNTISenti Biosciences-2.31%+6.03%-31.05%-34.88%-23.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORSCorsair PartneringN/AN/AN/AN/AN/AN/AN/AN/AGWIIGood Works II AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIQMDIntelligent Medicine AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ASNTISenti Biosciences2.7273 of 5 stars3.53.00.00.02.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORSCorsair Partnering 0.00N/AN/AN/AGWIIGood Works II Acquisition 0.00N/AN/AN/AIQMDIntelligent Medicine Acquisition 0.00N/AN/AN/ASNTISenti Biosciences 3.00Buy$8.50284.62% UpsideCurrent Analyst Ratings BreakdownLatest SNTI, GWII, IQMD, and CORS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/6/2025SNTISenti BiosciencesLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.005/2/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORSCorsair PartneringN/AN/A$0.44 per share23.37($0.49) per shareN/AGWIIGood Works II AcquisitionN/AN/AN/AN/A$0.07 per shareN/AIQMDIntelligent Medicine AcquisitionN/AN/AN/AN/AN/AN/ASNTISenti Biosciences$2.56M22.51N/AN/A$5.31 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORSCorsair Partnering$13.19MN/A0.00∞N/AN/A-80.72%3.55%N/AGWIIGood Works II Acquisition-$500KN/A0.00∞N/AN/A-22.76%-0.17%N/AIQMDIntelligent Medicine AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ASNTISenti Biosciences-$52.79M-$10.84N/AN/AN/AN/A-177.24%-67.38%8/12/2025 (Estimated)Latest SNTI, GWII, IQMD, and CORS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025SNTISenti Biosciences-$0.56-$1.41-$0.85-$1.41$1.30 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORSCorsair PartneringN/AN/AN/AN/AN/AGWIIGood Works II AcquisitionN/AN/AN/AN/AN/AIQMDIntelligent Medicine AcquisitionN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORSCorsair PartneringN/A0.490.49GWIIGood Works II AcquisitionN/A2.622.62IQMDIntelligent Medicine AcquisitionN/AN/AN/ASNTISenti BiosciencesN/A4.224.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORSCorsair Partnering80.11%GWIIGood Works II AcquisitionN/AIQMDIntelligent Medicine Acquisition56.63%SNTISenti Biosciences25.73%Insider OwnershipCompanyInsider OwnershipCORSCorsair PartneringN/AGWIIGood Works II Acquisition4.60%IQMDIntelligent Medicine Acquisition0.48%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORSCorsair Partnering2,02129.74 millionN/ANot OptionableGWIIGood Works II Acquisition2,0218.87 million8.47 millionNot OptionableIQMDIntelligent Medicine Acquisition2,0215.87 million5.84 millionNot OptionableSNTISenti Biosciences426.08 million25.27 millionNot OptionableSNTI, GWII, IQMD, and CORS HeadlinesRecent News About These CompaniesSenti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight SeriesJune 30 at 9:47 AM | quiverquant.comQSenti Bio Participates in Nasdaq Amplify Spotlight SeriesJune 30 at 9:15 AM | globenewswire.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - NasdaqJune 26, 2025 | nasdaq.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific TherapiesJune 24, 2025 | quiverquant.comQSenti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) ConferenceJune 24, 2025 | globenewswire.comSenti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug DesignationJune 18, 2025 | quiverquant.comQSenti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid LeukemiaJune 18, 2025 | globenewswire.comChardan Capital Reaffirms "Buy" Rating for Senti Biosciences (NASDAQ:SNTI)June 12, 2025 | marketbeat.comSenti Biosciences Announces New Employment Inducement GrantsJune 9, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 7, 2025 | prnewswire.comLaidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy RecommendationJune 7, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 6, 2025 | globenewswire.comSenti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLCJune 6, 2025 | globenewswire.comSenti Biosciences (NASDAQ:SNTI) Coverage Initiated at LaidlawJune 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 5, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 4, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 3, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 2, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 1, 2025 | prnewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) Short Interest UpdateJune 1, 2025 | marketbeat.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences IncMay 30, 2025 | accessnewswire.comAMedia Sentiment Over TimeSNTI, GWII, IQMD, and CORS Company DescriptionsCorsair Partnering NYSE:CORSCorsair Partnering Corporation does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar partnering transaction with one or more businesses. Corsair Partnering Corporation was incorporated in 2020 and is based in New York, New York.Good Works II Acquisition NASDAQ:GWIIGood Works II Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Houston, Texas.Intelligent Medicine Acquisition NASDAQ:IQMDIntelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science. The company was incorporated in 2021 and is based in Bethesda, Maryland.Senti Biosciences NASDAQ:SNTI$2.21 +0.10 (+4.74%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
